



2024 NATIONAL INVENTORS  
HALL OF FAME INDUCTEE

**Born:** Sept. 9, 1959

**Primary Connections:**

- University of Cambridge: Professor of Biophysical Chemistry, 1994-present; UK Dementia Research Institute, Group Leader
- Solexa (acquired by Illumina): Co-founder, 1998-2007
- BP Research: Laser Spectroscopy Group, 1987-94

**Education:**

- University of Cambridge: B.A., 1982; Ph.D., Chemistry, 1986

**Key Memberships/Awards:**

- Breakthrough Prize in Life Sciences, 2022
- Millennium Technology Prize, 2020
- The Royal Society: Royal Medal, 2018; Fellow, 2012
- Academy of Medical Sciences: Fellow, 2015

## 10 Things You Need to Know About

# David Klenerman

## Sequencing-by-Synthesis (SBS)

U.S. PATENT NO. 7,297,486

1. Born in 1959, Klenerman grew up in London.
2. While Klenerman engaged in many sports throughout his childhood, his father, a surgeon and professor, and his mother, a biological researcher, also placed an emphasis on education and the arts.
3. After completing his doctorate in chemistry in 1986 at the University of Cambridge, he was a Fulbright Scholar at Stanford University.
4. Thanks to Klenerman's and Shankar Balasubramanian's work, more than 1 million human genomes are sequenced each year.
5. He and Balasubramanian co-founded Solexa, which was acquired by Illumina.
6. Among his many honors, Klenerman has received the Breakthrough Prize in Life Sciences and the Millennium Technology Prize.
7. He is a fellow of the Royal Society and the Academy of Medical Sciences in the United Kingdom.
8. Klenerman was knighted in 2019 for services to science and for the development of high-speed DNA sequencing technology.
9. Klenerman is a group leader at the UK Dementia Research Institute at the University of Cambridge. His current research seeks to develop new insights on protein misfolding and neurodegenerative diseases.
10. He has nine U.S. patents.